The Future of Biomarker Tests and Genomic Medicine in Global organ disease

Research output: Contribution to conferenceAbstract

Abstract


• The induction of non alcoholic fatty liver disease (NAFLD) has become important to the treatment of diabetes in both the developed and developing world. Type 2 and Type 3 diabetes involves early brain disease and NAFLD that is expected to rise to 40% of the global population. Major interests in global communities with relevance to mitochondrial biogenesis has accelerated to reverse NAFLD and brain diseases. Early plasma biomarker diagnosis that may assist with mitochondrial biogenesis may be interpreted from lipidomic tests, genomic tests and proteomic tests. The levels of bacterial lipopolysaccharides (LPS) in plasma need to be carefully assessed with relevance to biomarker analysis. Biomarker analysis/analytes with relevance to diagnosis of organ disease may be incorrect and early LPS evaluation of patient plasma, cells and cerebrospinal fluid is required. LPS may induce various chronic diseases and may act as a competitive inhibitor to genes involved in mitochondrial biogenesis and prevention of NAFLD and brain aging. Multiple specialist tests are required to avoid inadvertent errors related to autonomous disease and repression of genes essential to maintain cell survival. The major defect in hepatocytes and neurons may indicate defective interaction between the nucleus and the mitochondria that leads to cell death and not diagnosed by biomarker tests. The future of plasma biomarkers need to be carefully revaluated and to accommodate early changes in immune system with relevance to interpretation of autoimmunity connected to NAFLD and diabetes in global populations.
Original languageEnglish
Publication statusPublished - 21 Aug 2017
EventGlobal Summit on Clinical Research and Biomarkers - Texas, United States
Duration: 21 Aug 201723 Aug 2017

Conference

ConferenceGlobal Summit on Clinical Research and Biomarkers
CountryUnited States
CityTexas
Period21/08/1723/08/17

Fingerprint

Biomarkers
Medicine
Organelle Biogenesis
Lipopolysaccharides
Brain Diseases
Essential Genes
Plasma Cells
Autoimmunity
Proteomics
Type 2 Diabetes Mellitus
Population
Cerebrospinal Fluid
Hepatocytes
Immune System
Cell Survival
Mitochondria
Chronic Disease
Cell Death
Non-alcoholic Fatty Liver Disease
Neurons

Cite this

Martins, I. (2017). The Future of Biomarker Tests and Genomic Medicine in Global organ disease. Abstract from Global Summit on Clinical Research and Biomarkers, Texas, United States.
Martins, Ian. / The Future of Biomarker Tests and Genomic Medicine in Global organ disease. Abstract from Global Summit on Clinical Research and Biomarkers, Texas, United States.
@conference{53670fd4d1b2486a815a6cb233e6cf9a,
title = "The Future of Biomarker Tests and Genomic Medicine in Global organ disease",
abstract = "• The induction of non alcoholic fatty liver disease (NAFLD) has become important to the treatment of diabetes in both the developed and developing world. Type 2 and Type 3 diabetes involves early brain disease and NAFLD that is expected to rise to 40{\%} of the global population. Major interests in global communities with relevance to mitochondrial biogenesis has accelerated to reverse NAFLD and brain diseases. Early plasma biomarker diagnosis that may assist with mitochondrial biogenesis may be interpreted from lipidomic tests, genomic tests and proteomic tests. The levels of bacterial lipopolysaccharides (LPS) in plasma need to be carefully assessed with relevance to biomarker analysis. Biomarker analysis/analytes with relevance to diagnosis of organ disease may be incorrect and early LPS evaluation of patient plasma, cells and cerebrospinal fluid is required. LPS may induce various chronic diseases and may act as a competitive inhibitor to genes involved in mitochondrial biogenesis and prevention of NAFLD and brain aging. Multiple specialist tests are required to avoid inadvertent errors related to autonomous disease and repression of genes essential to maintain cell survival. The major defect in hepatocytes and neurons may indicate defective interaction between the nucleus and the mitochondria that leads to cell death and not diagnosed by biomarker tests. The future of plasma biomarkers need to be carefully revaluated and to accommodate early changes in immune system with relevance to interpretation of autoimmunity connected to NAFLD and diabetes in global populations.",
author = "Ian Martins",
year = "2017",
month = "8",
day = "21",
language = "English",
note = "Global Summit on Clinical Research and Biomarkers ; Conference date: 21-08-2017 Through 23-08-2017",

}

Martins, I 2017, 'The Future of Biomarker Tests and Genomic Medicine in Global organ disease' Global Summit on Clinical Research and Biomarkers, Texas, United States, 21/08/17 - 23/08/17, .

The Future of Biomarker Tests and Genomic Medicine in Global organ disease. / Martins, Ian.

2017. Abstract from Global Summit on Clinical Research and Biomarkers, Texas, United States.

Research output: Contribution to conferenceAbstract

TY - CONF

T1 - The Future of Biomarker Tests and Genomic Medicine in Global organ disease

AU - Martins, Ian

PY - 2017/8/21

Y1 - 2017/8/21

N2 - • The induction of non alcoholic fatty liver disease (NAFLD) has become important to the treatment of diabetes in both the developed and developing world. Type 2 and Type 3 diabetes involves early brain disease and NAFLD that is expected to rise to 40% of the global population. Major interests in global communities with relevance to mitochondrial biogenesis has accelerated to reverse NAFLD and brain diseases. Early plasma biomarker diagnosis that may assist with mitochondrial biogenesis may be interpreted from lipidomic tests, genomic tests and proteomic tests. The levels of bacterial lipopolysaccharides (LPS) in plasma need to be carefully assessed with relevance to biomarker analysis. Biomarker analysis/analytes with relevance to diagnosis of organ disease may be incorrect and early LPS evaluation of patient plasma, cells and cerebrospinal fluid is required. LPS may induce various chronic diseases and may act as a competitive inhibitor to genes involved in mitochondrial biogenesis and prevention of NAFLD and brain aging. Multiple specialist tests are required to avoid inadvertent errors related to autonomous disease and repression of genes essential to maintain cell survival. The major defect in hepatocytes and neurons may indicate defective interaction between the nucleus and the mitochondria that leads to cell death and not diagnosed by biomarker tests. The future of plasma biomarkers need to be carefully revaluated and to accommodate early changes in immune system with relevance to interpretation of autoimmunity connected to NAFLD and diabetes in global populations.

AB - • The induction of non alcoholic fatty liver disease (NAFLD) has become important to the treatment of diabetes in both the developed and developing world. Type 2 and Type 3 diabetes involves early brain disease and NAFLD that is expected to rise to 40% of the global population. Major interests in global communities with relevance to mitochondrial biogenesis has accelerated to reverse NAFLD and brain diseases. Early plasma biomarker diagnosis that may assist with mitochondrial biogenesis may be interpreted from lipidomic tests, genomic tests and proteomic tests. The levels of bacterial lipopolysaccharides (LPS) in plasma need to be carefully assessed with relevance to biomarker analysis. Biomarker analysis/analytes with relevance to diagnosis of organ disease may be incorrect and early LPS evaluation of patient plasma, cells and cerebrospinal fluid is required. LPS may induce various chronic diseases and may act as a competitive inhibitor to genes involved in mitochondrial biogenesis and prevention of NAFLD and brain aging. Multiple specialist tests are required to avoid inadvertent errors related to autonomous disease and repression of genes essential to maintain cell survival. The major defect in hepatocytes and neurons may indicate defective interaction between the nucleus and the mitochondria that leads to cell death and not diagnosed by biomarker tests. The future of plasma biomarkers need to be carefully revaluated and to accommodate early changes in immune system with relevance to interpretation of autoimmunity connected to NAFLD and diabetes in global populations.

M3 - Abstract

ER -

Martins I. The Future of Biomarker Tests and Genomic Medicine in Global organ disease. 2017. Abstract from Global Summit on Clinical Research and Biomarkers, Texas, United States.